Arrowhead Pharmaceuticals, Inc.（ARWR）のニュースとイベントARWRArrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Reports Plozasiran Study Results, 79% Reduction in Triglycerides in Three Months

Arrowhead Pharmaceuticals presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia during a Hot Line Late-Breaking Science session at the European Society of Cardiology, ESC, Congress 2026 in Munich, Germany. SHASTA-3 and SHASTA-4 met their primary and all prespecified secondary endpoints and demonstrated deep and durable reductions in triglycerides, with median reductions from baseline of 79% and 81%, respectively at Month 12. In a prespecified pooled analysis, plozasiran also significantly reduced acute pancreatitis events across the broad sHTG study population, with greater absolute benefit observed among patients at higher risk of AP. More than 90% of plozasiran-treated patients in both studies achieved TG levels below 500 mg/dL at Month 12, and more than half achieved TG levels below 150 mg/dL.

Arrowhead Completes Enrollment in YOSEMITE Trial for Zodasiran

Arrowhead Pharmaceuticals announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company's investigational RNA iHnterference, RNAi, therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia, HoFH, a rare genetic condition that leads to severely elevated low density lipoprotein-cholesterol and early onset cardiovascular disease. Arrowhead anticipates that YOSEMITE will be completed in mid-2027 and, pending successful clinical results, intends to seek regulatory approval in multiple geographies thereafter.

Major Averages Close Fractionally Lower as Traders Remain Cautious

The major averages closed fractionally lower as traders take a cautious approach ahead of key earnings reports due from Alphabet, Tesla and IBM after the closing bell. Alphabet's report in particular will provide another major test of whether companies' heavy investments in artificial intelligence continue to generate meaningful returns and investors will closely scrutinize Alphabet's AI monetization strategy and cloud growth.Meanwhile, oil prices jumped once again as escalating tensions in the Middle East raise concerns over potential supply disruptions.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:AT&Treportedand reiterated its FY26 outlookGE Vernovareportedand raised its FY26 revenue guidanceAMDannounced aas part of a partnership to deploy up to 2 GW of AMD Instinct GPUsRepligenBioLife Solutionsfor $31 per share, or $1.5BThe European CommissionParamount Skydance'sproposed takeover of Warner Bros. Discovery2. WALL STREET CALLS:CoreWeaveto Buy at Truist after 42% pullbackPegasystemsto Market Perform at CitizensCircle Internetwith a Market Perform at Raymond JamesStifelDigitalOceanon selloff, positive data pointsTrimbleto Market Perform at Raymond James3. AROUND THE WEB:Amazonhas cut jobs in parts of its artificial general intelligence organization as it continues investing heavily in AI, WSJ reportsMeta'sinternal AI incubator is developing an AI model router, similar to OpenRouter's, to cut costs by sending some AI tasks to lower-cost models, The Information saysThe University of Tennessee Research Foundation sued Anthropic in Delaware federal court, arguing the company infringed its patents related to neural networks, Reuters saysPlatinum Equity is close to acquiring a 50% stake in Nestle'sEuropean water business through a joint venture that would value the San Pellegrino and Perrier owner at nearly EUR 5B, FT reportsAmgenhas reached a $74M settlement of a lawsuit accusing the company of waiting too long to disclose that it might owe the U.S. Internal Revenue Service $10.7B for underreporting six years of taxes, Reuters says4. MOVERS:Super Microgained afterArrowheadincreased after announcing its Phase 3 SHASTA-3 and SHASTA-4 studiesAirJoulewas higher after announcing with Kubota Corporationanin Texas and Californi aAdtranwas lower after providingDyne Therapeuticsfell after announcing a5. EARNINGS/GUIDANCE:Rogers Communications, with CEO Tony Staffieri saying the results "reflect strong execution"Moody'sand narrowed its guidance for FY26Teledyneand provided guidance for Q3 and FY26RPM, with EPS and revenue beating consensusTravel + Leisure, with CEO Michael Brown calling it "another strong quarter"INDEXES:The Dow fell 6.06, or 0.012%, to 52,218.58, the Nasdaq lost 146.31, or 0.57%, to 25,690.90, and the S&P 500 declined 10.24, or 0.14%, to 7,498.96.